435 related articles for article (PubMed ID: 27477685)
1. Redox-based therapeutics in neurodegenerative disease.
McBean GJ; López MG; Wallner FK
Br J Pharmacol; 2017 Jun; 174(12):1750-1770. PubMed ID: 27477685
[TBL] [Abstract][Full Text] [Related]
2. NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease.
Haslund-Vinding J; McBean G; Jaquet V; Vilhardt F
Br J Pharmacol; 2017 Jun; 174(12):1733-1749. PubMed ID: 26750203
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function.
Daiber A; Di Lisa F; Oelze M; Kröller-Schön S; Steven S; Schulz E; Münzel T
Br J Pharmacol; 2017 Jun; 174(12):1670-1689. PubMed ID: 26660451
[TBL] [Abstract][Full Text] [Related]
4. Microglia antioxidant systems and redox signalling.
Vilhardt F; Haslund-Vinding J; Jaquet V; McBean G
Br J Pharmacol; 2017 Jun; 174(12):1719-1732. PubMed ID: 26754582
[TBL] [Abstract][Full Text] [Related]
5. ROS in gastrointestinal inflammation: Rescue Or Sabotage?
Aviello G; Knaus UG
Br J Pharmacol; 2017 Jun; 174(12):1704-1718. PubMed ID: 26758851
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of oxidative stress: translational opportunities.
Daiber A; Di Lisa F; Ferdinandy P
Br J Pharmacol; 2017 Jun; 174(12):1511-1513. PubMed ID: 28555779
[TBL] [Abstract][Full Text] [Related]
8. New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.
Wilkins HM; Morris JK
Curr Pharm Des; 2017; 23(5):731-752. PubMed ID: 28034353
[TBL] [Abstract][Full Text] [Related]
9. Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases.
Arribas RL; Romero A; Egea J; de Los Ríos C
Br J Pharmacol; 2018 Aug; 175(16):3220-3229. PubMed ID: 29781146
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of NADPH oxidase 1/4 inhibitors.
Teixeira G; Szyndralewiez C; Molango S; Carnesecchi S; Heitz F; Wiesel P; Wood JM
Br J Pharmacol; 2017 Jun; 174(12):1647-1669. PubMed ID: 27273790
[TBL] [Abstract][Full Text] [Related]
11. Targetable Pathways for Alleviating Mitochondrial Dysfunction in Neurodegeneration of Metabolic and Non-Metabolic Diseases.
Millichap LE; Damiani E; Tiano L; Hargreaves IP
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768878
[TBL] [Abstract][Full Text] [Related]
12. Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.
Johnson DA; Johnson JA
Free Radic Biol Med; 2015 Nov; 88(Pt B):253-267. PubMed ID: 26281945
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria: a therapeutic target in neurodegeneration.
Moreira PI; Zhu X; Wang X; Lee HG; Nunomura A; Petersen RB; Perry G; Smith MA
Biochim Biophys Acta; 2010 Jan; 1802(1):212-20. PubMed ID: 19853657
[TBL] [Abstract][Full Text] [Related]
14. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.
Cappetta D; Esposito G; Coppini R; Piegari E; Russo R; Ciuffreda LP; Rivellino A; Santini L; Rafaniello C; Scavone C; Rossi F; Berrino L; Urbanek K; De Angelis A
Br J Pharmacol; 2017 Nov; 174(21):3696-3712. PubMed ID: 28320043
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy.
Palomo V; Nozal V; Rojas-Prats E; Gil C; Martinez A
Br J Pharmacol; 2021 Mar; 178(6):1316-1335. PubMed ID: 32737989
[TBL] [Abstract][Full Text] [Related]
16. Cross talk between mitochondria and NADPH oxidases.
Dikalov S
Free Radic Biol Med; 2011 Oct; 51(7):1289-301. PubMed ID: 21777669
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities.
Perez Ortiz JM; Swerdlow RH
Br J Pharmacol; 2019 Sep; 176(18):3489-3507. PubMed ID: 30675901
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dysfunction and oxidative stress in Alzheimer's disease, and Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis -An updated review.
Alqahtani T; Deore SL; Kide AA; Shende BA; Sharma R; Dadarao Chakole R; Nemade LS; Kishor Kale N; Borah S; Shrikant Deokar S; Behera A; Dhawal Bhandari D; Gaikwad N; Kalam Azad A; Ghosh A
Mitochondrion; 2023 Jul; 71():83-92. PubMed ID: 37269968
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2.
Cahill-Smith S; Li JM
Br J Clin Pharmacol; 2014 Sep; 78(3):441-53. PubMed ID: 25279404
[TBL] [Abstract][Full Text] [Related]
20. Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis.
Herrando-Grabulosa M; Gaja-Capdevila N; Vela JM; Navarro X
Br J Pharmacol; 2021 Mar; 178(6):1336-1352. PubMed ID: 32761823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
